Evidence map›Paper›PMID 41198910›Full record

ArticleCommunications chemistry2025

A fused deep learning approach to transform drug repositioning.

Kun Li, Jiacai Yi, Qing Ye, Xixi Yang, Long Yu, YouChao Deng, Chengkun Wu, Tingjun Hou, Dejun Jiang, Dongsheng Cao

Abstract read
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kun LiXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Jiacai YiXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Qing YeSchool of Computer Science, National University of Defense Technology, Changsha, China.
Xixi YangDeparment of Computer Science, Hunan University, Changsha, China.
Long YuHangzhou Carbonsilicon AI Technology Co., Ltd, Hangzhou, China.
YouChao DengXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Chengkun WuSchool of Computer Science, National University of Defense Technology, Changsha, China.ORCID http://orcid.org/0000-0002-9688-5311
Tingjun HouCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. tingjunhou@zju.edu.cn.ORCID http://orcid.org/0000-0001-7227-2580
Dejun JiangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China. jiang_dj@zju.edu.cn.ORCID http://orcid.org/0000-0002-2035-5074
Dongsheng CaoXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China. oriental-cds@163.com.ORCID http://orcid.org/0000-0003-3604-3785

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22173118, 22220102001, 22307112 and 82304316National Natural Science Foundation of China (National Science Foundation of China) 22307112
6 · The paper itself

Abstract

Drug repositioning holds promise for discovering new therapeutic applications for existing drugs, accelerating drug development and reducing associated costs. However, current methodologies encounter difficulties in managing diverse network representations, tackling cold start issues, and handling intrinsic attribute representations. Here we introduce a Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR), which integrates knowledge graph embedding, pre-training strategies, and recommendation systems to address these challenges. To overcome the cold start issue, UKEDR utilizes a semantic similarity-driven embedding approach. Our evaluations show that UKEDR performs better than various baselines, including classical machine learning, network-based, and deep learning approaches. In cold start scenarios, it demonstrates an improved capability in handling unseen nodes and generalizing to new compounds. The model also demonstrates strong robustness on imbalanced datasets and shows excellent generalization capabilities in specific drug-centric and disease-centric cold-start scenarios, validating its potential for real-world applications.

Identifiers

PMID41198910
PMCPMC12592385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.